Conduit Pharmaceuticals Stock Analysis

Conduit Stock Analysis Notes

About 26.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.59. Some equities with similar Price to Book (P/B) outperform the market in the long run. Conduit Pharmaceuticals recorded a loss per share of 179.34. The entity had not issued any dividends in recent years. The firm had 1:8 split on the 13th of October 2025. For more info on Conduit Pharmaceuticals please contact the company at 646 491 9132 or go to https://www.conduitpharma.com.

Conduit Pharmaceuticals Investment Alerts

Conduit Market Capitalization

The company currently falls under 'Nano-Cap' category with a total capitalization of 2.4 M.

Conduit Profitablity

Management Efficiency

Conduit Pharmaceuticals has Return on Asset of (2.0695) % which means that on every $100 spent on assets, it lost $2.0695. This is way below average. Conduit Pharmaceuticals' management efficiency ratios could be used to measure how well Conduit Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Conduit Pharmaceuticals' Return On Tangible Assets are comparatively stable compared to the past year. Return On Capital Employed is likely to gain to 2.23 in 2026, whereas Return On Assets are likely to drop (4.01) in 2026. Total Current Liabilities is likely to gain to about 13 M in 2026, whereas Liabilities And Stockholders Equity is likely to drop slightly above 3.2 M in 2026.

Technical Drivers

As of the 14th of February 2026, Conduit Pharmaceuticals shows the Standard Deviation of 7.26, mean deviation of 5.23, and Risk Adjusted Performance of (0.11). Conduit Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Conduit Pharmaceuticals Price Movement Analysis

Conduit Pharmaceuticals Insider Trading Activities

Conduit Pharmaceuticals Outstanding Bonds

Conduit Pharmaceuticals Predictive Daily Indicators

Conduit Pharmaceuticals Forecast Models

Conduit Pharmaceuticals' time-series forecasting models are one of many Conduit Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Conduit Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Conduit Pharmaceuticals Bond Ratings

Conduit Pharmaceuticals financial ratings play a critical role in determining how much Conduit Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Conduit Pharmaceuticals' borrowing costs.

Conduit Pharmaceuticals Total Assets Over Time

Conduit Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Conduit Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Conduit Pharmaceuticals Debt Ratio

168.0

It appears most of the Conduit Pharmaceuticals' assets are financed through debt. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Conduit Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Conduit Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Conduit Pharmaceuticals Corporate Bonds Issued

Conduit Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Conduit Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Conduit shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Conduit Pharmaceuticals. By using and applying Conduit Stock analysis, traders can create a robust methodology for identifying Conduit entry and exit points for their positions.

When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.